Guideline Recommendations for Managing Acute Mania in Patients Already Receiving Lithium Monotherapy

1. Combination‑Therapy Strategy

Adding an atypical antipsychotic to lithium is recommended over switching to a different mood stabilizer for patients with acute mania. Strong evidence supports this approach. [1][2]

Olanzapine – Demonstrated high efficacy when combined with lithium for acute manic episodes. Strong evidence. [1][2]
Aripiprazole – Holds FDA approval for the treatment of acute mania and is effective as an adjunct to lithium. [1][2]
Carbamazepine – Shows some supportive data for use with lithium, but the evidence is less robust compared with other atypicals. [1][2]

Metabolic adverse effects – Weight gain and metabolic disturbances are common, particularly with olanzapine and risperidone. Moderate‑level evidence. 3
Endocrine effects – Risperidone may increase prolactin levels and glucose concentrations. Moderate‑level evidence. 3
Sedation – Sedative effects are frequently reported across all atypical antipsychotics. Moderate‑level evidence. 3

Antidepressants – Adding antidepressants can destabilize mood and precipitate further manic symptoms. Strong evidence against use. [1][4]5
Gabapentin and topiramate – These agents have not demonstrated efficacy for acute mania. Strong evidence against use. [1][4]5
Benzodiazepines as primary therapy – Should not be used as the main treatment, although they may be useful for acute agitation or sleep disturbance. Strong evidence against primary use. [1][4]5

Maintain the lithium‑atypical antipsychotic combination for at least 4 weeks after acute stabilization to achieve lower relapse rates. Strong evidence. 3
After stabilization, clinicians should reassess the need for continued combination therapy versus returning to optimized lithium monotherapy. Moderate‑level evidence. [6][7]
For long‑term management, maintenance treatment should be continued for a minimum of 2 years following the last manic episode. Moderate‑level evidence. 6